MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
Public ClinicalTrials.gov record NCT04649359. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
MAGNETISMM-3 AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 2 STUDY OF ELRANATAMAB (PF-06863135) MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to evaluate whether single-agent Elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding of Elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.
Study identification
- NCT ID
- NCT04649359
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 187 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2, 2021 (Actual)
- Primary completion
- Jun 17, 2022 (Actual)
- Completion
- Aug 25, 2026 (Actual)
- Last update posted
- Oct 19, 2026
2021 – 2026
United States locations
- U.S. sites
- 37
- U.S. states
- 14
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Beverly Hills Cancer Center | Beverly Hills | California | 90211 | — |
| Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine | California | 92612 | — |
| The Regents of the University of California | Irvine | California | 92697 | — |
| UCLA Hematology/Oncology Clinic | Los Angeles | California | 90095 | — |
| UCLA Ronald Reagan Medical Center | Los Angeles | California | 90095 | — |
| UC Irvine Health - Chao Family Comprehensive Cancer Center | Orange | California | 92868 | — |
| Baptist Hospital of Miami | Miami | Florida | 33176 | — |
| Miami Cancer Institute | Miami | Florida | 33176 | — |
| Winship Cancer Institute @ Emory University Hospital Midtown | Atlanta | Georgia | 30308 | — |
| Emory University Hospital | Atlanta | Georgia | 30322 | — |
| Winship Cancer Institute, Emory University | Atlanta | Georgia | 30322 | — |
| Blood and Marrow Transplant Group of Georgia | Atlanta | Georgia | 30342 | — |
| Emory Saint Joseph's Hospital | Atlanta | Georgia | 30342 | — |
| Northside Hospital | Atlanta | Georgia | 30342 | — |
| Northwestern Medical Group | Chicago | Illinois | 60611 | — |
| Northwestern Memorial Hospital | Chicago | Illinois | 60611 | — |
| Loyola University Chicago performing research at Loyola University Medical Center | Maywood | Illinois | 60153 | — |
| Indiana Blood and Marrow Transplantation | Indianapolis | Indiana | 46237 | — |
| University of Iowa - Holden Comprehensive Cancer Center | Iowa City | Iowa | 52242 | — |
| Norton Cancer Institute, St. Matthews Campus | Louisville | Kentucky | 40207 | — |
| Norton Women's and Children's Hospital | Louisville | Kentucky | 40207 | — |
| Ochsner Clinic Foundation | New Orleans | Louisiana | 70121 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| John Theurer Cancer Center at Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Memorial Sloan Kettering Cancer Center-Investigational Drug Service Pharmacy | Long Island City | New York | 11101 | — |
| Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street). | New York | New York | 10021 | — |
| Weill Cornell Medical College - New York Presbyterian Hospital | New York | New York | 10021 | — |
| Weill Cornell Medical College - New York-Presbyterian Hospital | New York | New York | 10021 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Weill Cornell Medical College - New York Presbyterian Hospital | New York | New York | 10065 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| St. Francis Hospital | Greenville | South Carolina | 29601 | — |
| Saint Francis Hospital Cancer Center | Greenville | South Carolina | 29607 | — |
| St Francis Eastside | Greenville | South Carolina | 29615 | — |
| Baylor University Medical Center | Dallas | Texas | 75246 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04649359, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 19, 2026 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04649359 live on ClinicalTrials.gov.